Nika Pharmaceuticals Inc. (NIKA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Nika Pharmaceuticals Inc. (NIKA) trades at $0.77. Nika Pharmaceuticals, Inc. focuses on developing drugs for various diseases, including HIV/AIDS and cancer. Market cap: $806.33M, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for NIKA: NIKA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NIKA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NIKA: 1/1 perspectives are bearish.
How is this calculated? →Nika Pharmaceuticals Inc. (NIKA) Healthcare & Pipeline Overview
Nika Pharmaceuticals, Inc., based in Henderson, Nevada, develops and markets drugs and supplements targeting HIV/AIDS, hepatitis, rheumatoid arthritis, cancer, and diabetes. With a high profit margin despite a negative P/E ratio, the company operates in the competitive specialty and generic drug manufacturing industry, facing both opportunities and challenges in the OTC market.
What Is the Investment Thesis for NIKA?
Nika Pharmaceuticals presents a high-risk, high-reward investment profile. The company's extremely high profit margin of 33191.0% suggests potential profitability if revenue scales, but the negative P/E ratio of -15172.39 indicates current losses. Growth catalysts include potential FDA approvals for its drug pipeline and expansion into new therapeutic areas. However, the company's OTC listing and negative beta of -1.61 highlight volatility and market sensitivity. Investors should carefully assess the company's financial stability, regulatory risks, and competitive positioning before considering an investment. Success hinges on Nika's ability to successfully commercialize its drug candidates and achieve sustainable profitability.
Based on FMP financials and quantitative analysis
NIKA Key Highlights
- Market Cap of $806.33M indicates the company's current valuation in the OTC market.
- P/E Ratio of -15172.39 reflects current losses and high investor expectations for future earnings.
- Profit Margin of 33191.0% suggests significant potential for profitability if revenue scales effectively.
- Gross Margin of 100.0% indicates efficient cost management in the production of its products.
- Beta of -1.61 suggests the stock price moves inversely to the market, potentially offering diversification benefits but also indicating higher risk.
Who Are NIKA's Competitors?
NIKA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BHCCF Benchmark Holdings plc | $0.37 | +0.00% | $225.11M | 41 |
| CMVLF Cellectis S.A. | $3.47 | +12.66% | $251.93M | 51 |
| COGZF Cogstate Limited | $1.87 | +3.89% | $317.68M | 45 |
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NIKA's Key Strengths?
- High profit margin (33191.0%) indicates potential for profitability.
- Diverse product pipeline targeting multiple diseases.
- Proprietary drug formulations.
- Established presence in the dietary supplement market.
What Are NIKA's Weaknesses?
- Negative P/E ratio (-15172.39) indicates current losses.
- OTC listing suggests higher risk and lower liquidity.
- Limited financial resources compared to larger competitors.
- Dependence on successful drug development and regulatory approvals.
What Could Drive NIKA Stock Higher?
- Potential FDA approval for new drug candidates in the pipeline.
- Expansion into new geographic markets.
- Strategic partnerships and collaborations with other pharmaceutical companies.
- Development of biosimilar drugs.
- Research and development of personalized medicine approaches.
What Are the Key Risks for NIKA?
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for new drug candidates.
- Competition from larger, more established pharmaceutical companies.
- Patent expirations and generic competition.
- Stringent regulatory requirements and potential delays in drug approvals.
- Product liability lawsuits.
What Are the Growth Opportunities for NIKA?
- Expansion of Product Portfolio: Nika can expand its product portfolio by developing and commercializing new drugs for its existing therapeutic areas, such as HIV/AIDS, hepatitis, rheumatoid arthritis, cancer, and diabetes. The global market for these diseases is substantial, offering significant revenue potential. Successful development and approval of new drugs could drive significant revenue growth for Nika over the next 3-5 years.
- Strategic Partnerships and Acquisitions: Nika can pursue strategic partnerships and acquisitions to expand its product pipeline, access new technologies, and enter new markets. Collaborating with other pharmaceutical companies or acquiring smaller biotech firms could accelerate Nika's growth and enhance its competitive position. These partnerships can be established within the next 1-2 years.
- Geographic Expansion: Nika can expand its geographic reach by entering new markets, particularly in developing countries where there is a growing demand for affordable medicines. Expanding into new markets could significantly increase Nika's revenue and profitability over the next 3-5 years. This expansion requires navigating regulatory hurdles and establishing distribution networks.
- Development of Biosimilars: Nika can capitalize on the growing biosimilars market by developing and commercializing biosimilar versions of existing biologic drugs. The biosimilars market is expected to grow significantly in the coming years as patents for biologic drugs expire. Nika can launch its first biosimilar product within the next 2-3 years.
- Focus on Personalized Medicine: Nika can invest in personalized medicine approaches, such as developing targeted therapies based on individual patient characteristics. Personalized medicine is a rapidly growing field with the potential to revolutionize healthcare. Nika can begin clinical trials for personalized medicine within the next 3-4 years.
What Opportunities Does NIKA Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and acquisitions.
- Geographic expansion into developing countries.
- Development of biosimilar drugs.
What Threats Does NIKA Face?
- Competition from larger, more established pharmaceutical companies.
- Stringent regulatory requirements and potential delays in drug approvals.
- Patent expirations and generic competition.
- Product liability lawsuits.
What Are NIKA's Competitive Advantages?
- Proprietary drug formulations.
- Patents protecting its key products.
- Established relationships with distributors.
- Brand recognition in specific therapeutic areas.
What Does NIKA Do?
Nika Pharmaceuticals, Inc., incorporated in 2000 and based in Henderson, Nevada, is a pharmaceutical company focused on developing treatments for a range of diseases, including HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. Originally named Centennial Growth Equities Inc., the company rebranded to Nika Pharmaceuticals, Inc. in May 2022, signaling a strategic shift towards pharmaceutical development. Nika's product offerings include dietary supplements, antiviral drugs, and thymus nuclear glycoprotein, primarily targeting HIV. The company operates within the specialty and generic drug manufacturing sector, navigating the complexities of drug development, regulatory approvals, and market competition. Nika's business model encompasses research, development, and commercialization of pharmaceutical products, with a focus on addressing unmet medical needs in its target therapeutic areas. The company aims to provide accessible and effective treatments, contributing to improved patient outcomes and overall healthcare advancement. Nika Pharmaceuticals operates primarily in the United States, with potential for future expansion into international markets.
What Products and Services Does NIKA Offer?
- Develops drugs for the treatment of HIV/AIDS.
- Develops drugs for the treatment of hepatitis B and C.
- Develops drugs for the treatment of rheumatoid arthritis.
- Develops drugs for the treatment of cancer.
- Develops drugs for the treatment of diabetes.
- Offers dietary supplements.
- Offers antiviral drugs.
- Provides thymus nuclear glycoprotein for the treatment of HIV.
How Does NIKA Make Money?
- Develops and patents pharmaceutical products.
- Manufactures or outsources the manufacturing of its drugs.
- Markets and sells its products through distributors and direct sales.
- Generates revenue from the sale of its pharmaceutical products and supplements.
What Industry Does NIKA Operate In?
Nika Pharmaceuticals operates in the specialty and generic drug manufacturing industry, a sector characterized by intense competition, stringent regulatory requirements, and rapid technological advancements. The global pharmaceutical market is projected to reach trillions of dollars by 2026, driven by an aging population, increasing prevalence of chronic diseases, and advancements in drug discovery. Nika competes with larger, more established pharmaceutical companies, including ABTI, BHCCF, BHHKF, CMVLF, and COGZF, as well as smaller biotech firms. Success in this industry requires significant investment in research and development, a strong intellectual property portfolio, and effective marketing and distribution strategies.
Who Are NIKA's Key Customers?
- Patients suffering from HIV/AIDS.
- Patients suffering from hepatitis B and C.
- Patients suffering from rheumatoid arthritis.
- Patients suffering from cancer.
- Patients suffering from diabetes.
How Nika Pharmaceuticals Inc. Is Valued
Nika Pharmaceuticals Inc. carries a market capitalization of $806.33M, placing it in the small-cap category.
Company Profile
Nika Pharmaceuticals Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Henderson, US. The company is led by CEO Dimitar Slavchev Savov. NIKA has traded publicly since 2024.
ROE 27%Key Financial Metrics
Return on equity for Nika Pharmaceuticals Inc. stands at 27.4%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 1/9Financial Health
Nika Pharmaceuticals Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NIKA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- High profit margin (33191.0%) indicates potential for profitability.
- Diverse product pipeline targeting multiple diseases.
- Proprietary drug formulations.
- Established presence in the dietary supplement market.
Bear Case
- Negative P/E ratio (-15172.39) indicates current losses.
- OTC listing suggests higher risk and lower liquidity.
- Limited financial resources compared to larger competitors.
- Dependence on successful drug development and regulatory approvals.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NIKA Latest News
No recent news available for NIKA.
NIKA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NIKA.
Price Targets
Wall Street price target analysis for NIKA.
NIKA MoonshotScore
What does this score mean?
The MoonshotScore rates NIKA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Dimitar Slavchev Savov
CEO
Dimitar Slavchev Savov serves as the Chief Executive Officer of Nika Pharmaceuticals Inc. His professional background includes experience in the pharmaceutical and biotechnology sectors, though specific details on his prior roles and educational qualifications are not available. As CEO, he is responsible for overseeing the company's strategic direction, operations, and financial performance. His leadership is crucial for guiding Nika Pharmaceuticals through the challenges and opportunities of the competitive pharmaceutical market.
Track Record: Information on Dimitar Slavchev Savov's specific achievements and strategic decisions at Nika Pharmaceuticals is not available. Assessing his track record requires further information on key milestones achieved under his leadership, such as successful drug development programs, regulatory approvals, and financial performance improvements. His tenure and impact on the company's growth trajectory remain to be evaluated based on future performance and available data.
NIKA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Nika Pharmaceuticals may not meet the minimum financial or reporting standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosures, be undergoing restructuring, or face regulatory issues. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in Nika Pharmaceuticals.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosures and transparency.
- Higher risk of fraud and manipulation.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting or trading suspension.
- Lack of regulatory oversight and investor protection.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Understand the risks associated with investing in OTC Other stocks.
- Consult with a qualified financial advisor.
- Check for any regulatory actions or legal proceedings against the company.
- Company has been in operation since 2000.
- Development of drugs for serious diseases like HIV/AIDS and cancer.
- Presence in the dietary supplement market.
- Change of name in 2022 to reflect focus on pharmaceuticals.
What Investors Ask About Nika Pharmaceuticals Inc. (NIKA) — Healthcare
What does Nika Pharmaceuticals Inc. do?
Nika Pharmaceuticals Inc. is a pharmaceutical company that develops, manufactures, and markets drugs and supplements. Their primary focus is on treatments for diseases such as HIV/AIDS, hepatitis B and C, rheumatoid arthritis, cancer, and diabetes. In addition to prescription medications, they also offer dietary supplements and antiviral drugs. The company operates within the specialty and generic drug manufacturing sector, aiming to provide accessible and effective healthcare solutions.
What are the main risks for NIKA?
Nika Pharmaceuticals faces several key risks. Firstly, as a pharmaceutical company, it is subject to stringent regulatory requirements and the risk of delays or failures in obtaining drug approvals. Secondly, the company operates in a highly competitive industry and faces competition from larger, more established players. Thirdly, patent expirations and generic competition could erode its market share. Finally, its OTC listing exposes it to higher risks related to liquidity, transparency, and potential market manipulation.
How does Nika Pharmaceuticals Inc. navigate regulatory approval processes?
Information on Nika Pharmaceuticals Inc.'s specific FDA/EMA regulatory track record and pending approvals is not available. Pharmaceutical companies must adhere to rigorous clinical trial standards and documentation requirements to gain approval for new drugs. Compliance with Good Manufacturing Practices (GMP) is also critical for ensuring product quality and safety. Nika's success depends on its ability to navigate these complex regulatory pathways effectively and efficiently.
How does Nika Pharmaceuticals Inc. manage patent expiration risks?
Information on Nika Pharmaceuticals Inc.'s specific patent portfolio and lifecycle management strategies is not available. Pharmaceutical companies mitigate patent expiration risks through various strategies, including developing new formulations, securing additional patents for existing drugs, and diversifying their product pipeline. The emergence of biosimilar competition also poses a threat to companies with expiring patents. Nika's ability to innovate and protect its intellectual property is crucial for maintaining its competitive advantage.
What are the key factors to evaluate for NIKA?
Evaluate NIKA on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does NIKA data refresh on this page?
NIKA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NIKA's recent stock price performance?
Nika Pharmaceuticals Inc. (NIKA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: High profit margin (33191.0%) indicates potential for profitability. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NIKA overvalued or undervalued right now?
Valuing Nika Pharmaceuticals Inc. (NIKA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- OTC market data may be less reliable than exchange-listed data.
- AI analysis pending for NIKA.